tbuckley/cabot-search huggingface dataset:
ASSOCIATION OF NEW ONSET ATRIAL FIBRILLATION WITH ALL-CAUSE MORTALITY IN COVID 19 PATIENTS.
Authors: Kanaan Mansoor, Noor Ul Ann Rabbani, Ebad Ur Rahman, Salman Assad, Huma Nadeem Ahmed, Todd Gress, Gregg C. Fonarow, Mehiar El-Hamdani
Journal: Journal of the American College of Cardiology (2022)
PHYSICAL AND PSYCHOSOCIAL STATUS OF PARTICIPANTS WITH TAKOTSUBO CARDIOMYOPATHY
Authors: Jenna Maughan, Okezi Obrutu, Paul Marano, Benita Tjoe, Marie Lauzon, Romana Herscovici, Prizzi Moy, Thomas Rutledge, Chrisandra Shufelt, Janet Wei, C. Noel Bairey Merz
Journal: Journal of the American College of Cardiology (2022)
Abstract P3-20-10: Local recurrences after mammary adenectomy with clear retroareolar margin for the treatment of early infiltrating breast carcinomas
Authors: Rebeca Neves Heinzen, Alfredo CarlosSimõesDornellas de Barros, Alfredo Jacomo, Marcella Cinquini
Journal: Cancer Research (2022)

Abstract Introduction. Mammary adenectomy (MA) is an evolving surgical procedure for patients with breast cancer (BC). It entails the resection of all gross visible glandular tissue, while preserving the overlying breast skin envelope and the nipple-areolar complex (NAC). For achieving the best oncologic outcomes it is recommended the obtainance of clear surgical margins, mainly the retroareolar, and careful selection of the patients to be treated accordingly. Here, we performed a study aiming to assess the local recurrences rate in patients who underwent MA for BC therapy. Methods. A retrospective cross-sectional study was carried out at a private Service (Clínica Prof. Alfredo Barros). Patients with invasive BC measuring up to 3.0 cm and at least 2.0 cm far from the NAC by resonance magnetic imaging, were elegible, while others with more than 3 foci of neoplasia, nipple discharge or neoadjuvant chemotherapy were excluded. All of them were submitted to MA and selective axillary dissection and reconstruction by immediate prothesis implants, with clear retroareolar margin by intraoperative cytology and frozen section exams, and intra-nipple ducts excision. External radiotherapy was delivered when more than 3 affected axillary lymph nodes were involved. Results. A total of 18 cases were analysed. Patient’s mean age was 51.5 years. The histopathologic subtypes were: invasive carcinoma (NOS) 146 (80.7%), infiltrative lobular 26 (14.4%), micropapilar 3 (1.7%) and others 6 (3.3%). Mean tumor size was observed 1.8 cm (0.4-5.0). Multicentricity/multifocality was observed in 62 cases (34.2%) a total of 144 cases presented positivity for estrogen receptor (86.7%), 144 (79.6%) for progesterone receptor, and 29 were HER2 positive (16.0%). In 98 cases (54.1%) a small padge of skin covering the tumor area was removed. Irradiation was ministered to 50 patients (27.6%). After a mean follow up period of 39.9 months (6-178), ten cases of local recurrences were detected (5.5%). No one case of local relapse was detected in the sub-NAC area Conclusion. Our data indicated that the local recurrences rate after therapeutic MA for well selected BC patients is low and acceptable. 2 Citation Format: Rebeca Neves Heinzen, Alfredo CarlosSimõesDornellas de Barros, Alfredo Jacomo, Marcella Cinquini. Local recurrences after mammary adenectomy with clear retroareolar margin for the treatment of early infiltrating breast carcinomas [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-20-10.
Association of Remote History of Venous Thrombosis With Risk of Venous Thrombosis After Age 70 Years
Authors: Huijie Wang, Mary Cushman, Frits R. Rosendaal, Astrid van Hylckama Vlieg
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Previous venous thrombosis (VT) is associated with risk of future VT, but quantification of risk over the life course is poorly understood. More information is needed for clinicians to understand the association of remote history of VT with the risk of VT in older patients. <h3>Objective</h3> To assess the association between a remote history of VT and the development of VT in older age. <h3>Design, Setting, and Participants</h3> The Age and Thrombosis, Acquired and Genetic Risk Factors in the Elderly case-control study enrolled patients 70 years and older with VT and control individuals 70 years and older without VT between June 2008 and August 2011. The Age and Thrombosis, Acquired and Genetic Risk Factors in the Elderly study is a 2-center, population-based case-control study that was conducted in Burlington, Vermont, in the US and in Leiden, the Netherlands. Consecutively diagnosed patients with an objectively proven episode of VT (deep vein thrombosis of the leg or pulmonary embolism) were included. Control individuals were identified in the same geographic areas as the patients and were randomly selected. Data were analyzed between May 2021 and October 2021. <h3>Exposures</h3> Self-reported remote VT (occurring &gt;10 years before to enrollment). <h3>Main Outcomes and Measures</h3> The main outcome was the risk of VT at older age. The association of self-reported history of remote VT with VT at older age was assessed by calculating odds ratios (ORs) as estimates of relative risk with 95% CIs. <h3>Results</h3> A total of 460 patients with VT and 456 control participants were included. There were slightly more women than men in both groups (60.2% of patients [n = 277] were women and 52.4% of control participants [n = 239] were women), and the mean (range) age of patients was 78.7 (70.0-100.9) years, which was similar to the control participants. Compared with individuals without remote VT, those with a remote history of VT had an increased risk of VT (OR, 2.54; 95% CI, 1.56-4.13). The crude risk estimate was robust to adjustment and time since remote VT, that is, individuals with a VT 10 to 30 years ago (OR, 2.74; 95% CI, 1.34-5.57) and those with a VT more than 30 years ago (OR, 2.42; 95% CI, 1.21-4.84) had a an increased risk of VT. The population-attributable fraction of a remote history of VT was 7.7%. <h3>Conclusions and Relevance</h3> In this study, a remote history of VT was associated with risk of VT in older individuals. This quantification could assist clinicians in advising patients on VT prevention.
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
Authors: Anders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, Sheila Nainan Myatra, Bharath Kumar Tirupakuzhi Vijayaraghavan, Maria Cronhjort, Rebecka Rubenson Wahlin, Stephan M. Jakob, Luca Cioccari, Gitte Kingo Vesterlund, Tine Sylvest Meyhoff, Marie Helleberg, Morten Hylander Møller, Thomas Benfield, Balasubramanian Venkatesh, Naomi E. Hammond, Sharon Micallef, Abhinav Bassi, Oommen John, Vivekanand Jha, Klaus Tjelle Kristiansen, Charlotte Suppli Ulrik, Vibeke Lind Jørgensen, Margit Smitt, Morten H. Bestle, Anne Sofie Andreasen, Lone Musaeus Poulsen, Bodil Steen Rasmussen, Anne Craveiro Brøchner, Thomas Strøm, Anders Møller, Mohd Saif Khan, Ajay Padmanaban, Jigeeshu Vasishtha Divatia, Sanjith Saseedharan, Kapil Borawake, Farhad Kapadia, Subhal Dixit, Rajesh Chawla, Urvi Shukla, Pravin Amin, Michelle S. Chew, Christian Aage Wamberg, Neeta Bose, Mehul S. Shah, Iben S. Darfelt, Christian Gluud, Theis Lange, Anders Perner
Journal: Intensive Care Medicine (2022)
Magnetically responsive nanofibrous ceramic scaffolds for on-demand motion and drug delivery
Authors: Yonggang Zhang, Jiaping Li, Pamela Habibovic
Journal: Bioactive Materials (2022)

Smart biomaterials, featuring not only bioactivity, but also dynamic responsiveness to external stimuli, are desired for biomedical applications, such as regenerative medicine, and hold great potential to expand the boundaries of the modern clinical practice. Herein, a magnetically responsive three-dimensional scaffold with sandwich structure is developed by using hydroxyapatite (HA) nanowires and ferrosoferric oxide (Fe
SPONTANEOUS CORONARY ARTERY DISSECTION IN A PATIENT WITH MITOCHONDRIAL ENCEPHALOPATHY WITH LACTIC ACIDOSIS AND STROKE-LIKE EPISODES: A POSSIBLE UNDERLYING VASCULOPATHY?
Authors: Derek Schwabe-warf, Emily Hiltner, Bobby Ghosh, Theodore Maglione, Meghan Nahass
Journal: Journal of the American College of Cardiology (2022)
Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy
Authors: Xiaoxue Xie, Yi Feng, Hanxi Zhang, Qingqing Su, Ting Song, Geng Yang, Ningxi Li, Xiaodan Wei, Tingting Li, Xiang Qin, Shun Li, Chunhui Wu, Xiaojuan Zhang, Guixue Wang, Yiyao Liu, Hong Yang
Journal: Bioactive Materials (2022)

The clinical outcomes of cancer nanovaccine have been largely impeded owing to the low antigen-specific T cell response rate and acquired resistance caused by the immunosuppressive tumor microenvironment (TME). Here, we reported a tumor acidity-responsive nanovaccine to remodel the immunosuppressive TME and expand the recruitment of tumor infiltrating lymphocytes (TILs) using hybrid micelles (HM), which encapsulated colony stimulating factor 1 receptor (CSF1-R) inhibitor BLZ-945 and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG-919 in its core and displayed a model antigen ovalbumin (OVA) on its surface (denoted as BN@HM-OVA). The bioactive nanovaccine is coated with a polyethylene glycol (PEG) shell for extending nanoparticle circulation. The shell can be shed in response to the weakly acidic tumor microenvironment. The decrease in size and the increase in positive charge may cause the deep tumor penetration of drugs. We demonstrated that the bioactive nanovaccine dramatically enhance antigen presentation by dendritic cells (DCs) and drugs transportation into M1-like tumor-associated macrophages (TAMs) and tumor cells via size reduction and increasing positive charge caused by the weakly acidic TME. Such bioactive nanovaccine could remodel the immunosuppressive TME into an effector T cells favorable environment, leading to tumor growth inhibition in prophylactic and therapeutic E.G7-OVA tumor models. Furthermore, combining the bioactive nanovaccine with simultaneous anti-PD-1 antibody treatment leads to a long-term tumor inhibition, based on the optimal timing and sequence of PD-1 blockade against T cell receptor. This research provides a new strategy for the development of efficient cancer immunotherapy.
Single‐cell transcriptomics of mouse lung reveal inflammatory memory neutrophils in allergic asthma
Authors: Zhiwei Li, Yufan Feng, Haitao Liu, Hongqin Yang, Jinqiu Li, Yitian Zhou, Junling Pang, Peiran Yang, Hongmei Zhao, Jing Wang
Journal: Allergy (2022)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
SURVIVAL OF PATIENTS WITH RHEUMATIC AND NON-RHEUMATIC MITRAL VALVE STENOSIS AFTER VALVULOPLASTY
Authors: Shazil Mahmood, David Gelovani, Kartik Gupta, Michael Chiang, Pedro Engel-Gonzales, Tiberio M. Frisoli, Pedro Arturo Villablanca, James Chihong Lee, Dee Dee Wang, Janet Fredal Wyman, Brian O’Neill, William O’Neill, Marvin H. Eng
Journal: Journal of the American College of Cardiology (2022)
DIMENSIONLESS INDEX COMPLEMENTS TRANSVALVULAR FLOW RATE IN SOLVING DISCORDANT LOW GRADIENT AORTIC STENOSIS
Authors: Mayooran Namasivayam, Timothy Churchill, Romain Capoulade, Philippe Pibarot, Jacqueline Suk Danik, Michael H. Picard, Robert A. Levine, Judy W. Hung
Journal: Journal of the American College of Cardiology (2022)
RESISTIN AND RISK OF SUBCLINICAL HEART FAILURE AND CARDIAC FIBROSIS: THE MULTIETHNIC STUDY OF ATHEROSCLEROSIS (MESA) STUDY
Authors: Xinjiang Cai, Matthew A. Allison, Bharath Ambale Venkatesh, Neal Jorgensen, Joao A.C. Lima, Evan D. Muse, Robyn McClelland, Steven Shea, Djamel Lebeche
Journal: Journal of the American College of Cardiology (2022)
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Authors: Eric L. Ross, Marc S. Weinberg, Steven E. Arnold
Journal: JAMA Neurology (2022)

Several anti-amyloid monoclonal antibodies have been developed for slowing the progression of Alzheimer disease (AD). Among the furthest developed are aducanumab, which received accelerated approval from the US Food and Drug Administration in 2021, and donanemab, which is currently undergoing phase 3 trials. The cost-effectiveness of these treatments has not been established.
Abstract P2-10-07: Prediction of menstruation recovery timing in premenopausal breast cancer patients taking tamoxifen after chemotherapy: An ASTRRA substudy
Authors: Young Joo Lee, Woo C Noh, Seok J Nam, Byeong-Woo Park, Eun S Lee, Seock A Im, Yong S Jung, Jung H Yoon, Sung S Kang, Kyong H Park, Soo-Jung Lee, Min H Lee, Joon Jeong, Sung Y Kim, Hyun-Ah Kim, Se-Hwan Han, Wonshik Han, Min H Hur, Seonok Kim, Sei-hyun Ahn, Hee J Kim
Journal: Cancer Research (2022)

Abstract Introduction Addition of ovarian function suppression to conventional endocrine therapy alone in premenopausal women provides a survival benefit with moderate to high risk hormone-receptor positive breast cancer, especially who received chemotherapy Prediction of menstruation recovery after chemotherapy is important for deciding subsequent endocrine treatment and addressing fertility issues. Methods In the adding OFS after chemotherapy trial (ASTRRA), patients who resumed ovarian function up to 2 years after chemotherapy were randomized to receive either 5 years of tamoxifen or adding 2 years of OFS with tamoxifen. With these 1383 patients, we developed a model that predicts when patients recover menstruation within 3 years after chemotherapy using several variables including age, BMI, chemotherapy regimen and duration, serum E2 and FSH level. Results A total of 1017 patients data were used to develop prediction model and 366 patients data were used for external validation. In development group, 546 (53.6%) patients resumed menstruation during follow up period of 5 years. In multivariable analysis, younger age and AC based regimen without taxane were strong predictive factor for menstruation recovery. However predictive value of chemotherapy regimen was not constant over time. Therefore, we conducted another model with patients (n= 624) who did not recover menstruation within one year. In this patient group, predictive factors for menstruation recovery was age and serum E2 level at 6 months after chemotherapy. We also conducted a simplified scoring system to estimate change of recovery by using risk factors mentioned above. Conclusion Younger age is an important persisting factor predicting menstrual recovery after chemotherapy. Although chemotherapy regimen predicts shor-term menstrual recovery, over time, patient factors have more predictive influence on recovery. Recovery of serum E2 level would be important to predict subsequent menstruation recovery. Citation Format: Young Joo Lee, Woo C Noh, Seok J Nam, Byeong-Woo Park, Eun S Lee, Seock A Im, Yong S Jung, Jung H Yoon, Sung S Kang, Kyong H Park, Soo-Jung Lee, Min H Lee, Joon Jeong, Sung Y Kim, Hyun-Ah Kim, Se-Hwan Han, Wonshik Han, Min H Hur, Seonok Kim, Sei-hyun Ahn, Hee J Kim. Prediction of menstruation recovery timing in premenopausal breast cancer patients taking tamoxifen after chemotherapy: An ASTRRA substudy [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-10-07.
EICOSAPENTAENOIC ACID (EPA) INCREASES HEME OXYGENASE-1 EXPRESSION IN MACROPHAGES AND ENDOTHELIAL CELLS DURING INFLAMMATION
Authors: Samuel CR R. Sherratt, Peter Libby, Deepak L. Bhatt, Hazem Dawoud, Tadeusz Malinski, R. Preston Mason
Journal: Journal of the American College of Cardiology (2022)
Making child’s play of tolerance: Defining the immune‐viral interplay during combination entecavir and pegylated interferon therapy for immune‐tolerant hepatitis B infection
Authors: Jessica Howell, Margaret Hellard
Journal: Hepatology (2022)

Dr. Howell receives education speaker's fees from Eisai, unrelated to this work. She receives investigator-initiated, peer-reviewed grant support from Gilead. Dr. Hellard receives funding from Gilead Sciences and Abbvie for investigator-initiated research unrelated to this work.
1α,25(OH)<sub>2</sub>D<sub>3</sub>reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
Authors: Peng Li, Xinhai Zhu, Guangchao Cao, Ruan Wu, Ke Li, Wenhui Yuan, Biyun Chen, Guodong Sun, Xichun Xia, Hua Zhang, Xiao Wang, Zhinan Yin, Ligong Lu, Yunfei Gao
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Epidemiological surveys have revealed that low serum vitamin D level was correlated with increased risk of tumors. Dysfunctional T cells in patients with tumor are characterized as exhausted with high levels of immune checkpoint receptors (ICRs). However, whether the reduced level of vitamin D in patients with cancer correlates with cytotoxic T-cell exhaustion is unknown. Methods Periphery blood samples from 172 patients with non-small cell lung cancer (NSCLC) were prospectively collected. Patients with NSCLC received one course of intravenous docetaxel (75 mg/m 2 ) followed by treatment with or without rocaltrol at a dose of 0.5–2.0 µg/day for total of 3 weeks. We performed phenotypical and functional analysis of T-cell through flow cytometry. Vitamin D receptor (VDR) knockout and overexpression CD8 + and Vδ2 + T cells were constructed using Cas9-gRNA targeted and overexpressing approaches to identify 1α,25(OH) 2 D 3 /VDR-mediated transcription regulation for ICRs or antitumor activity in T cells. Results We show that serum level of vitamin D is negatively correlated with expression of programmed cell death-1 (PD-1), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and T-cell immunoglobulin and mucin-domain containing-3 (Tim-3), but positively correlated with CD28 expression on CD8 + and Vγ9Vδ2 + T cells in patients with NSCLC. 1α,25(OH) 2 D 3 , the active form of vitamin D, promotes the nuclear translocation of VDR, which binds to the promoter region of Pdcd1 , Tim3 , and Tigit genes and inhibits their expression. Besides, 1α,25(OH) 2 D 3 pretreatment also promotes the methylation of CpG island in the promoter region of the Pdcd1 gene and increases H3K27 acetylation at the promoter region of the Cd28 gene, which leads to surface PD-1 downregulation and CD28 upregulation, respectively. We further reveal that VDR-mediated Ca 2+ influx enhanced expression of Th1 cytokines via T-cell receptor activation. Functionally, 1α,25(OH) 2 D 3 pretreated CD8 + T cells or Vγ9Vδ2 + T cells showed increased Th1 cytokine production and enhanced antitumor immunity. Finally, oral 1α,25(OH) 2 D 3 could also decrease expression of PD-1, Tim-3, TIGIT and increase expression of CD28, resulting in cytokine production (associated with antitumor immunity) by cytotoxic T cells of patients with NSCLC. Conclusions Our findings uncover the pleiotropic effects of 1α,25(OH) 2 D 3 in rescuing the exhausted phenotype of human cytotoxic T cells in patients with tumor and in promoting their antitumor immunity. Trial registration number ChiCTR2100051135.
Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients
Authors: Christina Zeller, Daniel Richter, Vindi Jurinovic, Ilse A. Valtierra-Gutiérrez, Ashok Kumar Jayavelu, Matthias Mann, Johannes W. Bagnoli, Ines Hellmann, Tobias Herold, Wolfgang Enard, Binje Vick, Irmela Jeremias
Journal: Journal of Hematology & Oncology (2022)

Abstract Acute myeloid leukemia (AML) patients suffer dismal prognosis upon treatment resistance. To study functional heterogeneity of resistance, we generated serially transplantable patient-derived xenograft (PDX) models from one patient with AML and twelve clones thereof, each derived from a single stem cell, as proven by genetic barcoding. Transcriptome and exome sequencing segregated clones according to their origin from relapse one or two. Undetectable for sequencing, multiplex fluorochrome-guided competitive in vivo treatment trials identified a subset of relapse two clones as uniquely resistant to cytarabine treatment. Transcriptional and proteomic profiles obtained from resistant PDX clones and refractory AML patients defined a 16-gene score that was predictive of clinical outcome in a large independent patient cohort. Thus, we identified novel genes related to cytarabine resistance and provide proof of concept that intra-tumor heterogeneity reflects inter-tumor heterogeneity in AML.
Abstract P4-07-30: Residual lymphovascular invasion: Predicts the outcome of neoadjuvant chemotherapy in locally advanced breast cancer
Authors: Omima Elemam, Khaled Elnaghi, Ziad Emarah, Hossam Alghanami, Seham Abdelkhalek
Journal: Cancer Research (2022)

Abstract Background: Lymphovascular invasion (LVI) is known to be associated with a poor outcome in breast cancer patients. It indicates a highly proliferative cancer. Few studies examined the value of LVI as a predictor for outcome after neoadjuvant chemotherapy (NAC). The aim of this study to look for an association between survival outcomes and clinicopathological features in locally advanced breast cancer patients treated with NAC and to identify the predictors of nodal pathologic complete response (PCR). Methods:This study is a retrospective analysis of 224 women with locally advanced breast cancer who underwent NAC between 2011-2020. Kaplan-Meier analyses were used to assess the associations between disease-free survival (DFS) and overall survival (OS) and all clinicopathological variables including LVI in breast surgical specimens following NAC. Associations between nodal PCR and all clinicopathologic variables were assessed Results:Median follow-up was 29.9 months. Absence of nodal PCR (p.000), positive family history (p .027), clinical T4 (p.049), pathological TNM staging (p.016), high tumor grade (p .020),triple negative disease(p .016) and absence of tumor PCR (p.001) were associated with worse disease free survival. Absence of nodal PCR (p.002), high BMI (p.039), multicentric disease (p.026), high tumor grade, triple negative disease (p.018), and absence of tumor PCR (p.005) were associated with worse overall survival. LVI was found in 53 of surgical specimens (23.7%). It was associated with worse DFS (HR) (2.967) 95% CI (1.7-4.9), p.000 and overall survival (HR) (3.05) 95% CI (1.525-6.09), p.002). Nodal PCR significantly correlated with T stage (p .013), LVI (p.000), ER status (p.004), PR status (p.003), Her2neu status and IHC score (p.000), tumor subtype (p.000), tumor PCR (p.000), DFS (p.000), and OS (p.000). Conclusion:LVI is significantly associated with worse DFS and OS in locally advanced breast cancer patients treated with NAC. This data confirmed the previously published recommendation to add LVI to the pathological staging system. LVI may be further explored as a guide for adjuvant treatment options in clinical trials. Nodal PCR is another significant predictor of outcome and is associated significantly with tumor PCR and LVI. Both tumor PCR and LVI can be used as criteria for axillary surgery omission in future trials. Citation Format: Omima Elemam, Khaled Elnaghi, Ziad Emarah, Hossam Alghanami, Seham Abdelkhalek. Residual lymphovascular invasion: Predicts the outcome of neoadjuvant chemotherapy in locally advanced breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-30.